Literature DB >> 6163457

Covalent attachment of immunoglobulins to liposomes via glycosphingolipids.

T D Heath, B A Macher, D Papahadjopoulos.   

Abstract

We describe a method for covalent binding of proteins to large unilamellar liposomes which involves the periodate oxidation of glycosphingolipids in the vesicle membrane. Proteins such as IgG and F(ab')2 may then be attached to the aldehyde groups on the glycolipid by Schiff-base formation at pH 9.5 and reduction with NaBH4, or by reductive amination with NaBH3CN at pH 8.4. Exposure of the vesicles to periodate, protein coupling and separation from unbound protein by a novel method of flotation is discontinuous dextran gradients does not release the vesicle contents when performed at pH 8.4. Studies on the oxidation of neutral glycolipid-containing vesicles, and on the oxidation of encapsulated glycerol 1-phosphate show that periodate influx into neutral vesicles during a 4 h exposure is appreciable at pH 5.5 but not at pH 8.4. Under optimal conditions, approx. 20% of the protein may be coupled to vesicles, and a ratio of 100--200 microgram of protein/mumol of lipid is readily achieved. This method will be of great importance for the antibody-mediated targeting of vesicles to cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163457     DOI: 10.1016/0005-2736(81)90532-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

Review 1.  Effectiveness of an intermittent fasting diet versus continuous energy restriction on anthropometric measurements, body composition and lipid profile in overweight and obese adults: a meta-analysis.

Authors:  Andrea Enríquez Guerrero; Ismael San Mauro Martín; Elena Garicano Vilar; María Alicia Camina Martín
Journal:  Eur J Clin Nutr       Date:  2020-12-09       Impact factor: 4.016

2.  Recognition of liposome-bound antigens by antipeptide antibody.

Authors:  Y Sohma; R Fujita; S Katoh; E Sada
Journal:  Appl Biochem Biotechnol       Date:  1993-03       Impact factor: 2.926

Review 3.  Immunoglobulins as targeting agents for liposome encapsulated drugs.

Authors:  P A Toonen; D J Crommelin
Journal:  Pharm Weekbl Sci       Date:  1983-12-16

4.  Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate.

Authors:  T D Heath; J A Montgomery; J R Piper; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

5.  Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.

Authors:  Tanaya Vaidya; Robert M Straubinger; Sihem Ait-Oudhia
Journal:  Pharm Res       Date:  2018-03-13       Impact factor: 4.200

6.  Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model.

Authors:  Fiona Y Glassman; Sathy V Balu-Iyer
Journal:  Int J Pharm       Date:  2018-07-05       Impact factor: 5.875

7.  Incorporation of hormone-sensitive lipase into phosphatidylcholine vesicles.

Authors:  C Holm; G Fredrikson; R Sundler; P Belfrage
Journal:  Lipids       Date:  1990-05       Impact factor: 1.880

8.  Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia.

Authors:  Rong Deng; Joseph P Balthasar
Journal:  Blood       Date:  2006-11-28       Impact factor: 22.113

9.  Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.

Authors:  Karthik Ramani; Razvan D Miclea; Vivek S Purohit; Donald E Mager; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-04       Impact factor: 3.534

10.  Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.

Authors:  Karthik Ramani; Vivek Purohit; Razvan Miclea; Puneet Gaitonde; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.